Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00494013 · ClinicalTrials.gov registry record · Phase 3
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT00494013: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00494013 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 442 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00494013, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.
Interventions
- DRUG Detemir
- DRUG Insulin Lispro Protamine Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00494013 record still lists
NCT00494013 is an interventional study that assigns participants to a tested intervention. The registered 442 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Detemir is the first listed.
NCT00494013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00494013 about?
NCT00494013 is a clinical study titled "Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)". The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.
What is the current status of trial NCT00494013?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2007-08. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00494013?
The interventions under investigation include: Detemir (DRUG), Insulin Lispro Protamine Suspension (DRUG).
Who is sponsoring clinical trial NCT00494013?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00494013's enrollment target sits among peer trials
442 867th of 2000 higher than 1,134 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT06659029 · 442 participants
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia